• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

IL-23 inhibitor treatment of immune checkpoint inhibitor-associated psoriasis: Case series and review of literature.

作者信息

Bourand Natalie, Kuraitis Drew, Lema Bethany, Pei Susan

机构信息

University of Illinois College of Medicine, Chicago, Illinois.

Department of Dermatology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

出版信息

JAAD Case Rep. 2024 Nov 10;56:33-37. doi: 10.1016/j.jdcr.2024.09.027. eCollection 2025 Feb.

DOI:10.1016/j.jdcr.2024.09.027
PMID:39845461
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11750480/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b68/11750480/9207ca65961d/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b68/11750480/e50b0e3679aa/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b68/11750480/b5871bdb0818/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b68/11750480/9207ca65961d/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b68/11750480/e50b0e3679aa/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b68/11750480/b5871bdb0818/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b68/11750480/9207ca65961d/gr3.jpg

相似文献

1
IL-23 inhibitor treatment of immune checkpoint inhibitor-associated psoriasis: Case series and review of literature.白细胞介素-23抑制剂治疗免疫检查点抑制剂相关银屑病：病例系列及文献综述
JAAD Case Rep. 2024 Nov 10;56:33-37. doi: 10.1016/j.jdcr.2024.09.027. eCollection 2025 Feb.
2
Cardiovascular adverse events and immune-related adverse events associated with PD-1/PD-L1 inhibitors for head and neck squamous cell carcinoma (HNSCC).与 PD-1/PD-L1 抑制剂相关的头颈部鳞状细胞癌（HNSCC）的心血管不良事件和免疫相关不良事件。
Sci Rep. 2024 Oct 29;14(1):25919. doi: 10.1038/s41598-024-75099-5.
3
Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.PD-1/PD-L1 免疫检查点抑制剂的皮肤毒性不良反应：发病机制、治疗和监测。
Cutan Ocul Toxicol. 2022 Mar;41(1):73-90. doi: 10.1080/15569527.2022.2034842. Epub 2022 Feb 20.
4
Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma.帕博利珠单抗诱导的斑块状银屑病在一名IV期皮肤黑色素瘤患者中用司库奇尤单抗成功治疗。
Melanoma Res. 2023 Apr 1;33(2):152-154. doi: 10.1097/CMR.0000000000000875. Epub 2022 Dec 27.
5
Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review.寻常型银屑病在PD-1检查点抑制剂治疗期间病情加重：病例报告及文献综述
Case Rep Dermatol. 2018 Aug 9;10(2):190-197. doi: 10.1159/000491572. eCollection 2018 May-Aug.
6
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
7
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.药物生存分析：白细胞介素（IL）-17 和 IL-23 抑制剂治疗银屑病的回顾性多国、多中心队列研究。
Am J Clin Dermatol. 2022 Nov;23(6):891-904. doi: 10.1007/s40257-022-00722-y. Epub 2022 Aug 17.
8
PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review.PD-1/PD-L1 抑制剂相关免疫性血小板减少症：一项药物警戒研究和系统评价。
Int Immunopharmacol. 2024 Mar 10;129:111606. doi: 10.1016/j.intimp.2024.111606. Epub 2024 Feb 14.
9
Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis.古塞单抗治疗银屑病关节炎的疗效比较：系统文献回顾和网络荟萃分析的更新。
Rheumatology (Oxford). 2023 Apr 3;62(4):1417-1425. doi: 10.1093/rheumatology/keac500.
10
Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.意大利一项为期 28 周的回顾性研究：真实世界中古塞库单抗、里莎鲁单抗和替西珠单抗的间接比较。
J Dermatolog Treat. 2022 Sep;33(6):2813-2820. doi: 10.1080/09546634.2022.2081655. Epub 2022 May 29.

引用本文的文献

1
[New-onset nail psoriasis after treatment with pembrolizumab and durvalumab].[帕博利珠单抗和度伐利尤单抗治疗后新发甲银屑病]
Dermatologie (Heidelb). 2025 May;76(5):300. doi: 10.1007/s00105-025-05496-y. Epub 2025 Apr 1.

本文引用的文献

1
Psoriasis in the Era of Targeted Cancer Therapeutics: A Systematic Review on De Novo and Pre-existing Psoriasis in Oncologic Patients Treated with Emerging Anti-neoplastic Agents.靶向癌症治疗时代的银屑病：关于接受新型抗肿瘤药物治疗的肿瘤患者新发和既往存在银屑病的系统评价
Dermatol Ther (Heidelb). 2024 Jul;14(7):1755-1766. doi: 10.1007/s13555-024-01198-w. Epub 2024 Jun 22.
2
Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitors.鉴定免疫相关模式，以特征性免疫反应在接受抗 PD-1 检查点抑制剂治疗的肿瘤患者中的银屑病。
Front Immunol. 2024 Mar 1;15:1346687. doi: 10.3389/fimmu.2024.1346687. eCollection 2024.
3
The use of biologic medications for the treatment of cutaneous immune-related adverse events secondary to immune checkpoint inhibitors: A single-institution real-life study.
生物制剂用于治疗免疫检查点抑制剂继发的皮肤免疫相关不良事件：一项单机构真实世界研究。
JAAD Case Rep. 2023 Nov 2;43:1-3. doi: 10.1016/j.jdcr.2023.09.041. eCollection 2024 Jan.
4
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis. Guselkumab 在银屑病和银屑病关节炎的 11 项 II/III 期临床研究的综合分析：长期安全性。
Drug Saf. 2024 Jan;47(1):39-57. doi: 10.1007/s40264-023-01361-w. Epub 2023 Oct 31.
5
The use of interleukin-23 inhibitors to treat immune-related psoriasis induced by immune checkpoint inhibitors and in patients with active cancer: A case series and review of the literature.白细胞介素-23抑制剂用于治疗免疫检查点抑制剂诱导的免疫相关性银屑病及活动性癌症患者：病例系列及文献综述
SAGE Open Med Case Rep. 2023 Jun 16;11:2050313X231181035. doi: 10.1177/2050313X231181035. eCollection 2023.
6
Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma.帕博利珠单抗诱导的斑块状银屑病在一名IV期皮肤黑色素瘤患者中用司库奇尤单抗成功治疗。
Melanoma Res. 2023 Apr 1;33(2):152-154. doi: 10.1097/CMR.0000000000000875. Epub 2022 Dec 27.
7
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.免疫疗法毒性的管理：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2022 Dec;33(12):1217-1238. doi: 10.1016/j.annonc.2022.10.001. Epub 2022 Oct 18.
8
Guselkumab for treating immune checkpoint inhibitor-induced psoriatic arthritis.古塞库单抗用于治疗免疫检查点抑制剂诱导的银屑病关节炎。
Ann Rheum Dis. 2022 Sep 12;81(10):1479-1480. doi: 10.1136/annrheumdis-2022-222628.
9
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.免疫检查点抑制剂在伴有既往银屑病患者中的安全性和疗效。
J Immunother Cancer. 2021 Oct;9(10). doi: 10.1136/jitc-2021-003066.
10
Apremilast for immune checkpoint inhibitor-induced psoriasis: A case series.阿普斯特治疗免疫检查点抑制剂诱导的银屑病：病例系列
JAAD Case Rep. 2021 Mar 13;11:84-89. doi: 10.1016/j.jdcr.2021.03.015. eCollection 2021 May.